Kaisa Health Group Holdings Limited released its unaudited results for the six months ended 30 June 2026.

Financial performance • Revenue slid 15.80% year on year to HK$0.28 billion, reflecting an 18.11% fall in pharmaceutical sales. • Gross profit decreased 23.13% to HK$0.11 billion; gross margin narrowed to 37.9% (H1 2025 restated: 41.5%). • The Group recorded a loss before tax of HK$67.18 million (H1 2025: profit HK$2.86 million) and a net loss of HK$62.48 million (H1 2025: profit HK$2.71 million). • Loss attributable to shareholders was HK$60.17 million; basic and diluted loss per share stood at HK1.24 cents (H1 2025: loss HK7.67 cents, restated).

Segment review • Pharmaceutical Business: Revenue HK$219.85 million, down 18.11%; segment loss before tax HK$26.10 million. • Dental Business: Revenue HK$60.53 million, down 8.88%; segment loss HK$18.16 million. • Health Care (sports rehabilitation): Revenue HK$4.21 million, up 33.90%; segment loss HK$18.57 million. Combined segment loss before tax totalled HK$62.83 million.

Balance sheet highlights (30 June 2026) • Cash and bank balances: HK$33.37 million (31 Dec 2025: HK$137.89 million). • Net current liabilities: HK$669.07 million. • Total borrowings: HK$399.94 million; of which HK$75.07 million are current. • Provision for financial guarantee liabilities: HK$685.62 million. • Equity attributable to owners in deficit at HK$322.78 million (31 Dec 2025: deficit HK$294.50 million).

Capital and corporate actions • Completed acquisition of Embrace Blossom Limited on 24 June 2026 for HK$24.41 million, satisfied by issuing 2.79 million new shares. • Implemented a 50-into-1 share consolidation on the same day, reducing issued shares to 103.63 million. • No interim dividend declared.

Post-period event The board proposes renaming the company to “Qinghai Biotech Pharmaceutical Group Limited (青海生物製藥集團有限公司)”, subject to shareholder and regulatory approvals.